Insider · CIK 0001722140
Abraham Ceesay
ceoofficerdirector
Files at CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.), PCRX (Pacira BioSciences, Inc.), RAPP (Rapport Therapeutics, Inc.). First filing Sep 8, 2025, latest Oct 8, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 10
$0 bought, $4.2M sold
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
RAPP: Rapport Therapeutics, Inc.
RAPPOct 9, 2026 · close 30.65
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
PCRX: Pacira BioSciences, Inc.
PCRXOct 9, 2026 · close 36.31
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | Rapport Therapeutics, Inc. | $143k 4,522 shares | -1% | +28% from low-41% from high | |
| 22Weak | Rapport Therapeutics, Inc. | $87k 2,210 shares | -0% | +40% from low-35% from high | |
| 20Weak | Rapport Therapeutics, Inc. | $374k 8,210 shares | -2% | - | |
| 27Weak | Rapport Therapeutics, Inc. | $320k 10,916 shares | -2% | +308% from low-8% from high | |
| 27Weak | Rapport Therapeutics, Inc. | $285k 10,916 shares | -2% | +263% from low-19% from high | |
| 27Weak | Rapport Therapeutics, Inc. | $324k 10,916 shares | -2% | +301% from low-9% from high | |
| 34Weak | Rapport Therapeutics, Inc. | $275k 10,916 shares | -2% | +251% from low-20% from high | |
| 27Weak | Rapport Therapeutics, Inc. | $282k 10,916 shares | -2% | +261% from low-18% from high | |
| 50Moderate | Rapport Therapeutics, Inc. | $2.0M 76,420 shares | -12% | +268% from low-16% from high | |
| 8Weak | Pacira BioSciences, Inc. | $64k 2,354 shares | -21% | +110% from low-2% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,375 | $32.03 | $108k | 453,392 | 4 d ago |
| Oct 7, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,147 | $30.66 | $35k | 452,245 | 4 d ago |
| Sep 23, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,952 | $39.05 | $76k | 457,025 | 18 d ago |
| Sep 23, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -215 | $39.86 | $8,570 | 456,810 | 18 d ago |
| Sep 23, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -43 | $41.05 | $1,765 | 456,767 | 18 d ago |
| Sep 8, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,141 | $45.56 | $325k | 460,046 | 33 d ago |
| Sep 8, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,069 | $46.01 | $49k | 458,977 | 33 d ago |
| Feb 18, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,552 | $29.05 | $103k | 558,528 | Feb 19, 2026 |
| Feb 18, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,281 | $29.80 | $68k | 556,247 | Feb 19, 2026 |
| Feb 18, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,983 | $29.04 | $87k | 22,829 | Feb 19, 2026 |
| Feb 18, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,100 | $29.80 | $63k | 20,729 | Feb 19, 2026 |
| Feb 2, 2026 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +428,000 | $0.00 | $0 | 428,000 | Feb 4, 2026 |
| Jan 20, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,833 | $26.12 | $152k | 562,080 | Jan 22, 2026 |
| Jan 20, 2026 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -5,083 | $26.11 | $133k | 25,812 | Jan 22, 2026 |
| Dec 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,441 | $28.84 | $70k | 571,305 | Dec 18, 2025 |
| Dec 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,792 | $30.04 | $84k | 568,513 | Dec 18, 2025 |
| Dec 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -600 | $31.04 | $19k | 567,913 | Dec 18, 2025 |
| Dec 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,147 | $28.84 | $62k | 33,831 | Dec 18, 2025 |
| Dec 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,421 | $30.04 | $73k | 31,410 | Dec 18, 2025 |
| Dec 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -515 | $31.04 | $16k | 30,895 | Dec 18, 2025 |
| Nov 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,777 | $24.92 | $69k | 576,802 | Nov 18, 2025 |
| Nov 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,056 | $25.43 | $78k | 573,746 | Nov 18, 2025 |
| Nov 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,242 | $24.91 | $56k | 38,819 | Nov 18, 2025 |
| Nov 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,841 | $25.44 | $72k | 35,978 | Nov 18, 2025 |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,647 | $25.72 | $120k | 580,765 | Oct 16, 2025 |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,186 | $26.14 | $31k | 579,579 | Oct 16, 2025 |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -4,328 | $25.75 | $111k | 41,816 | Oct 16, 2025 |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -755 | $26.17 | $20k | 41,061 | Oct 16, 2025 |
| Sep 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -39,435 | $26.30 | $1.0M | 586,812 | Sep 19, 2025 |
| Sep 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,400 | $26.87 | $38k | 585,412 | Sep 19, 2025 |
| Sep 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -34,885 | $26.30 | $918k | 46,844 | Sep 19, 2025 |
| Sep 17, 2025 | RAPP Rapport Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -700 | $27.04 | $19k | 46,144 | Sep 19, 2025 |
| Sep 4, 2025 | PCRX Pacira BioSciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,354 | $27.19 | $64k | 9,039 | Sep 8, 2025 |
| Jun 11, 2025 | PCRX Pacira BioSciences, Inc. | AGrant or award Common Stock | +6,163 | $0.00 | $0 | 11,393 | Jun 13, 2025 |
| Jun 11, 2025 | PCRX Pacira BioSciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +11,279 | $0.00 | $0 | 11,279 | Jun 13, 2025 |
| Jun 2, 2025 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Common Stock | +946 | $135.04 | $128k | 946 | Jun 4, 2025 |
| Jun 2, 2025 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Stock Options (Right to Buy)derivative | +2,082 | $135.04 | $281k | 2,082 | Jun 4, 2025 |
| Feb 3, 2025 | RAPP Rapport Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +428,000 | $0.00 | $0 | 428,000 | Feb 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.